In this study, we systematically investigated the prognostic value of EIF4G1 in BRCA, determined the association of EIF4G1 with tumor-infiltrating immune cells (TIICs) and immunotherapy response, and screened for potential drugs against BRCA. This evidence concerns the gene EIF4G1 and neoplasm.